Work

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.2547.2547

Authors: Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Mojca Jongen-Lavrencic, Jessica K. Altman, Hartmut Dohner, Blythe Thomson, Stephen J. Blakemore, Scott Daigle, Greg Fine, Nigel J. Waters, Andrei V Krivstov, Richard Koche, Scott A. Armstrong, Peter T Ho, Bob Lowenberg, Martin S Tallman

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Duke Medical Center, Mayo Clinic in Arizona, Sarah Cannon, Erasmus MC, Northwestern University, University Hospital Ulm, Epizyme (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2584347108

FWCI: 5.88

Cites:

Cited by: 47

Related to: 10